ELISpot and Fluorospot Assay Market Size 2022 to 2030 - Quantitative Research by QYResearch Medical

The global ELISpot and Fluorospot Assay market was valued at USD 123.5 million in 2018 and is expected to reach USD 408.8 million by the year 2030, at a CAGR of 15.9%.

The global ELISpot and Fluorospot Assay market was valued at USD 123.5 million in 2018 and is expected to reach USD 408.8 million by the year 2030, at a CAGR of 15.9%. The ELISpot and Fluorospot assay techniques are for analyzing the immune system at a single-cell level. The technique uses microplates, which are coated by antibodies on which sample cells are cultured. The antibodies arrest the specific molecules released by the cells. The techniques are widely used in the research and development of various infectious diseases and significantly in cancer research.

The rising awareness about the diagnosis of various infections is expected to propel the industry widely. Moreover, government funding provided to various companies for R&D is giving rise to innovative products in the sector. The increasing prevalence of chronic disorders and rising incidences of cancer has led to a huge growth of the industry. Also, the rising cases of infectious diseases that can be diagnosed using ELISpot and fluorospot assay are also expected to drive the sector extensively. Many key players have launched innovative products in the industry, propelling the sector growth intensely. Companies are improving the ELISpot and Fluorospot kits and analyzers using various technological advancements, which might anticipate industry growth.

Inquiry Before Buying@ https://qyresearchmedical.com/submit-inquiry/118286

From the regional point of view, the North American region is expected to grow at a high pace due to increasing technological advancements in the region. Moreover, the presence of various key players in the region is expected to be a growth factor for the region. Asia Pacific region is highly prone to various chronic diseases due to the presence of a high geriatric population.

The limited availability of high-quality detection reagents used in the assay techniques and high sensitivity of the assay methods could be some restraints for the industry. Moreover, the presence of other efficient technologies in the industry which serve the same purpose as the ELISpot and Fluorospot assay may hinder the growth.

Related Reports:

Key Coverage of the Report

  • Region and country-wise assessment from the period 2019-2030. For the study, 2019-2017 has been utilized as historical data, 2018 as the base year, and 2019-2030, has been derived as forecasts
  • Regional Competitors clinical pipeline analysis
  • Demand and Supply GAP Analysis
  • Market share analysis of the key industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 6 years of all the mentioned segments, and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments

Salient Trends of the ELISpot and Fluorospot Assay Market

  • The innovative technological advancements have extensively propelled the industry. New devices are being launched by industry players to maintain their position in the industry.
  • For instance in the year 2019, Lophius Biosciences again launched new products, namely ELISpot MultiTrack 12 x 8-well PVDF microtiter strip plate. The plate has a high protein binding capacity, as well as the plates, were protected using sidewalls, making it system friendly and easy to use.
  • To continue its strong presence in the healthcare sector, Lophius Biosciences another product in 2017, the next generation of T Track CMV, an Immune Monitoring Tool. The test is used for risk stratification of human cytomegalovirus in transplant patients.
  • Regionally, North America has the highest segment share, whereas the Asia Pacific is known to grow in the industry at a faster pace. The strong presence of a huge population in the Asia Pacific, the prevalence of chronic disorders, and rising incidences of cancer are expected to drive the industry widely.
  • Furthermore, according to the estimates given by the American Cancer Society, more than 1.8 million new cancer cases are expected to be diagnosed in the year 2020. Such a high prevalence of cancer provides opportunities for key players in the sector.

Companies considered and profiled in this market study

The major key players in the company include, Oxford Immunotec, Cellular Technologies, Mabtech, Becton Dickinson and Company, Abcam, Bio-Techne, U-Cytech Biosciences, Lophius Biosciences GmbH and Biotech Investissement Group.

Market-O-Nomics

  • The North American regional segment held the largest share in the ELISpot and Fluorospot assay sector of 37.1% in the year 2018. Its dominance can be attributed to the increase in investments in R&D activities and due to increasing prevalence of chronic diseases in the region
  • The assay kits segment is expected to reach USD 214.5 million by the year 2030, showing significant growth during the forecast period
  • In 2018, analyzers segment was valued at USD 34.8 million and is expected to grow at a CAGR of 15.6%
  • The diagnostics segment is expected to grow with a CAGR of 15.7% during the forecast period
  • The cancer segment is expected to reach USD 74.5 million by the year 2030, owing to the increasing research in cancer diagnosis and treatment
  • Asia-Pacific regional segment of the industry is expected to remain highest growing segment during 2019-2030, at a CAGR of 16.9%. The area is growing at a faster rate due to prevalence of a large geriatric population which is prone to various chronic diseases.

Segments covered in the report

This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the market trends in each of the sub-segments from 2019 to 2030. For the purpose of this study, Reports and Data have segmented the ELISpot and Fluorospot assay market on the basis of product, application, end use and region:

Inquiry Before Buying@ https://qyresearchmedical.com/submit-inquiry/118286

By Product (Revenue in Million USD; 2019–2030)

  • Assay Kits
    • B cell assay
    • T cell assay
  • Ancillary products
  • Analyzers

By Application (Revenue in Million USD; 2019–2030)

  • Cancer
  • Diagnostics
    • Transplants
    • Infectious diseases
  • Vaccines
  • Clinical trials
  • Others

By End Use (Revenue in Million USD; 2019–2030)

  • Research Institutes
  • Diagnostic Centers
  • Hospital and clinics
  • Ambulatory surgical centers
  • Others

Regional Outlook (Revenue in Million USD; 2019–2030)

  • North America
    • U.S
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of the Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America
    • Brazil

Buy quantitative research Report at discounted price - USD 1500 https://qyresearchmedical.com/report/checkout/118286/1500

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

About Us

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.

For Latest Update Follow Us:

URL - http://www.qyresearchmedical.com/

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi